Boston Scientific (BSX) Land & Improvements (2025 - 2026)

Boston Scientific (BSX) posted quarterly Land & Improvements of $183.0 million for Q2 2026, down 2.66% on a QoQ basis from $188.0 million in Q1 2026.

Boston Scientific (BSX) Land & Improvements (2025 - 2026) Analysis & Trends

Boston Scientific has reported Land & Improvements for 2 years, with the latest figure at $183.0 million in Q2 2026.

Land & Improvements for Q2 2026 came in at $183.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $183.0 million (changed N/A YoY), and the FY2025 annual result was $173.0 million, changed N/A from the prior year.
Land & Improvements slipped to $183.0 million in Q2 2026, from $188.0 million in the prior quarter.
Over five years, Land & Improvements peaked at $188.0 million in Q1 2026 and troughed at $173.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Land & Improvements (Qtr)
1	Abbott Laboratories	199.24 Bn	193.64 Bn	7.27 Bn	-
2	Stryker	128.63 Bn	125.15 Bn	4.50 Bn	1.81 Bn
3	Medtronic	119.19 Bn	109.97 Bn	6.41 Bn	-
4	Boston Scientific	73.51 Bn	72.97 Bn	3.85 Bn	183.00 Mn
5	Edwards Lifesciences	52.11 Bn	47.85 Bn	1.35 Bn	-
6	Dexcom	34.64 Bn	32.70 Bn	830.00 Mn	-
7	GE HealthCare Technologies	34.01 Bn	31.90 Bn	2.18 Bn	-
8	Koninklijke Philips	26.40 Bn	23.08 Bn	4.55 Bn	-
9	Steris	23.14 Bn	22.65 Bn	684.20 Mn	112.50 Mn
10	Zimmer Biomet Holdings	19.32 Bn	18.91 Bn	1.54 Bn	-

Download Data